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ABSTRACT
Objective: To evaluate the cost-effectiveness of implementing
a universal infant 7-valent pneumococcal conjugate vaccine
(PCV7) vaccination program in the Irish health-care setting
from the health-care payers’ perspective.
Methods: A model was constructed in MS Excel to follow a
cohort of vaccinated and unvaccinated individuals from birth
over a 5-year period. The reduction in events that would be
associated with PCV7 vaccination and the mortality and cost
resulting from these events were analyzed. In a separate sub-
model, the effect of herd immunity was investigated.
Results: Implementing a PCV7 vaccine program in Ireland in
a birth cohort of 61,000 infants would be expected to prevent
7703 cases of pneumococcal-related infections over 5 years,
resulting in costs avoided of €2.05 million increasing to €4.6
million if the effect of herd immunity was included. The
baseline incremental cost-effectiveness ratio was €249,591/
life years gained (LYG), which reduced to €5997/LYG when
the effect of herd immunity was included.
Conclusions: A universal infant pneumococcal conjugate
vaccination could be considered highly cost-effective in the
Irish health-care setting from a health-care payers’ perspec-
tive, if viewed in terms of the herd immunity effect. The
results of this study have positive ramiﬁcations for countries
in the early stages of health technology assessment.
Keywords: childhood, cost-effectiveness, herd immunity,
pneumococcal conjugate vaccination.
Introduction
Many cost-effectiveness evaluations of childhood
pneumococcal conjugate vaccination strategies have
been published in the literature. Beutels et al. compiled
a recent review of 15 economic evaluations of 7-valent
pneumococcal conjugate vaccine (PCV7) vaccination
programs, published between 2002 and 2006 [1]. They
found a wide variation between studies in terms of
data inputs and assumptions (e.g., vaccine efﬁcacy
parameters and incidence rates). The results varied
from total net savings to over €100,000 per quality-
adjusted life-year. The authors of the review concluded
that when the observed herd immunity effects from the
United States are included, and a three-dosage sched-
ule can be assumed to be as effective as a four-dosage
schedule, childhood PCV7 vaccination, at the current
vaccine price, is likely to be judged as relatively cost-
effective to the health-care payer, and potentially cost
saving to society. It appears that, at least in the short
term, the cost-effectiveness of this program is expected
to be attractive. Nevertheless, it is clear that country-
speciﬁc estimates of parameters, such as incidence of
pneumococcal disease and cost of vaccination, can
inﬂuence the outcome of the economic evaluation.
Given the high investment costs associated with
this vaccination program, the decision to implement
it should be based on sound assessments of its
population effectiveness, budget impact and cost-
effectiveness. Given the country-speciﬁc nature of the
prevalence of circulating pneumococcal serotypes, and
the costs of treatment for associated clinical disease,
such assessments are likely to differ from one country
to the next.
The objective of this evaluation was to evaluate the
cost-effectiveness of implementing a universal infant
PCV7 vaccination program in Ireland as compared to
no vaccination.
Methods
Base-Case Model (without Herd Immunity)
A model was constructed to follow a cohort of vacci-
nated and unvaccinated individuals from birth over a
5-year period. The number of LYG from the vaccina-
tion program was the primary outcome of the
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program, and this was compared to the net cost, i.e.,
the additional cost of universal vaccination minus the
expected savings from reduced use of health-care
resources, because of a reduction in the burden of
pneumococcal disease.
The analysis was performed using MS Excel 2000.
The model is run in cycles of 6 months each, with the
exception of the ﬁrst year of age which was divided
into three age bands: 0 to 2 months, 2 to 6 months,
and 6 to 12 months. Age-speciﬁc background mortal-
ity was based on life tables from the Irish Central
Statistics Ofﬁce. The reduction in events that would be
associated with PCV7 vaccination and the mortality
and cost resulting from these events were analyzed.
The model only considered the four major out-
comes for which clinical trial data were available
regarding vaccine efﬁcacy: pneumonoccal meningitis,
pneumococcal septicemia, all-cause pneumonia, and
all-cause acute otitis media (AOM).
In this evaluation, invasive pneumococcal disease
(IPD) included meningitis and septicemia. IPD is
always treated in the hospital. Meningitis can lead to
long-term complications (hearing loss, focal neurologi-
cal deﬁcits, development delay, or chronic seizures) or
death. Outcomes from the septicemia health state are
either death or recovery with no sequelae.
Noninvasive pneumococcal infections include
pneumonia and AOM. Pneumonia can be treated in
either primary or secondary care, and outcomes
include either death or recovery with no sequelae.
AOM may result in hospital admission with surgical
intervention (i.e., myringotomy with ventilation tube
insertion). Therefore, the burden of all-cause pneumo-
nia and all-cause AOMwith vaccine efﬁcacy data from
clinical trials against all-cause pneumonia and all-
cause AOM was included in the model because the
burden of pneumococcal-speciﬁc infection was difﬁcult
to establish.
The “no vaccination” arm portrayed the present
epidemiological situation. Under the “vaccination”
arm, the probability of each outcome at each age was
reduced in proportion to the expected population
effectiveness of the immunization program.
Herd Immunity Model
A submodel was constructed to investigate the impact
of vaccination on unvaccinated adults (i.e., herd
immunity). Recent studies have highlighted the signiﬁ-
cant impact of the herd immunity effect on the cost-
effectiveness of a universal PCV7 vaccination program
[2–5]. The herd immunity model is similar to the infant
cohort model described previously, but is modiﬁed in
terms of population structure and time horizon. It is
assumed that indirect protection will be conferred on
the unvaccinated adult population for a period of
1 year [6], i.e., a 32% (95% CI 23–39%) reduction in
IPD in the 20 to 39 years old age group, an 8% (95%
CI 1–15%) reduction in IPD in the 40 to 64 years old
age group, and an 18% (95% CI 11–24%) reduction
in IPD in those over 65 years. A similar indirect effect
was demonstrated for hospital-treated pneumonia in
adults [7] as presented in Table 1. There is currently no
published evidence available to demonstrate the indi-
rect effect of vaccination on community-treated pneu-
monia and AOM.
Table 1 Incidence data for herd immunity model: cases per 1000 patients per time period
Age bands Septicemia [2] Meningitis [2] Pneumonia (hospital) [2]
20–24 0.018 0.002 0.18
25–44 0.031 0.003 0.26
45–64 0.065 0.005 0.55
65–74 0.187 0.009 1.936
75+ 0.425 0.006 6.977
Mortality data for herd immunity model: cases per 1000 patients per time period
Age bands Pneumococcal septicemia [2] Pneumococcal meningitis [2] All-cause pneumonia (hospital) [2]
20–24 0.014 0.00 0.00162
25–44 0.036 0.01 0.00162
45–64 0.047 0.02 0.00756
65–74 0.0486 0.03 0.01566
75+ 0.072 0.04 0.02484
Percentage reduction in incidence of events in vaccinated patients by age and disease
Age bands
Septicemia (efﬁcacy against covered
pneumococcal subtype) [6]
Meningitis (efﬁcacy against covered
pneumococcal subtype) [6]
Hospital pneumonia (effect against all
pneumonia) [7]
20–24 0.32 0.32 0.26
25–44 0.32 0.32 0.26
45–64 0.08 0.08 0.19
65–74 0.18 0.18 0.15
75+ 0.18 0.18 0.15
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The herd immunity effects were fed back into the
original model to form one integrated model.
Model Assumptions
A list of assumptions is included in Table 2. Parameters
varied in the sensitivity analysis are shown in Table 3
and other epidemiological data inputs are shown in
Table 4.
Results
Baseline Costs and Effects
In the base-case scenario, the model estimated the
number of cases of pneumococcal infection and the
number of deaths averted in a birth cohort of 61,000
infants if a universal PCV7 vaccination schedule was
introduced (Table 5).
The number of cases of pneumococcal infection and
the number of deaths prevented in a cohort of 2.98
million adults was estimated for the herd immunity
submodel (Table 5).
The total cost of the three-dosage vaccine schedule,
including an administration fee of €15 per dose, would
be approximately €12.2 million per year for a birth
cohort of 61,000 infants (Table 5). Pneumococcal-
related disease was estimated to cost €2.05 million less
in a vaccinated cohort because of cost savings from
avoided pneumococcal disease among the vaccinated
cohort. Cost savings of €4.6 million from avoided
pneumococcal disease were estimated if the effect of
herd immunity was included in the model (Table 5).
Baseline Incremental Cost-Effectiveness Ratio (ICER)
The baseline ICER, excluding herd effects, was
€249,591 per LYG and €5997/LYG when the effect of
herd immunity was included.
Discussion
The results of this economic evaluation suggest that
including PCV7 vaccine in the childhood immunization
program in Ireland would be highly cost-effective, if the
effect of herd immunity is included in the model. The
intervention is substantially less cost-effective if the
herd immunity effect is not taken into account. There is
considerable uncertainty in some of the model param-
eters, but this does not change the overall conclusion of
the evaluation, as shown in the sensitivity analysis.
The ﬁnding that this indirect effect of the vaccine
has a positive impact on the cost-effectiveness of the
PCV7 vaccine has also been demonstrated in other
recent economic evaluations of PCV7 vaccination
[3–5]. The Norwegian government included PCV7 in
the vaccination program in the autumn of 2005. More
recently, Grijalva et al. [7], using administrative data,
have provided further evidence of the herd immunity
effect from routine pneumococcal vaccination of chil-
dren and infants, where a reduction in hospitalized
Table 2 Assumptions used in the base-case and herd immunity models, including direct medical costs
Model assumptions Base-case model Herd immunity model
Vaccination strategies Three-dosage schedule (i.e., two doses separated by a
2-month period and third dose at 13 months of age).
Vaccine efﬁcacy IPD 93.9% (CI 79.9–98.5%) [11] Reduction in cases of IPD [6] and hospital
pneumonia [7]All-cause pneumonia (positive ﬁlm)
17.7% (CI 4.8–28.9%) [12]
All-cause AOM 7% (CI -5–17%) [13]
Serotypes producing invasive disease in
Ireland accounted for [14].
Vaccine onset 50% vaccine efﬁcacy 2–6 months
100% vaccine efﬁcacy 6 months-5 years
Duration of protection 5 years Vaccination of one infant cohort reduces
incidence of neumococcal infection in adults
for 1 year [6].
Vaccine uptake 85% [15]
Vaccine costs Ex-wholesale price €63.18 plus administration fee €15/dose
Total cost per infant per course €234.54
Direct medical costs Adapted to Irish setting from UK expert panel [16]
Pneumococcal infection Pneumococcal meningitis €7352 Meningitis €7330*
Pneumococcal septicemia €5467 Septicemia €6810*
All-cause pneumonia €2283 Hospital-treated pneumonia €4618*
All-cause AOM €148
Long-term sequelae of meningitis Adapted to Irish setting from UK resource utilization
costs/infection (discounted over
10 years)
Hearing loss €35,925
Developmental delay €61,875
Focal neurological deﬁcits €58,802
Chronic seizures €12,458
Discounting Costs and beneﬁts discounted annually at 3.5%
*AR-DRG data, National Casemix Unit, Dept. of Health & Children Ireland, 2005.
AOM, acute otitis media; IPD, invasive pneumococcal disease.
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pneumonia has been observed not only for the target
group for vaccination (i.e., children less than 2 years),
but also in the 18 to 39 years old age group The
reduction in all-cause pneumonia in vaccinated and
unvaccinated populations illustrates again how the
value of the vaccine has far exceeded expectations
documented by Ray et al. [5].
Nevertheless, after the introduction of the universal
vaccination program, nonvaccine serotypes may well
replace vaccine serotypes, leading to a smaller reduc-
tion in disease burden over time. Singleton et al. [8]
have recently demonstrated this effect in Alaskan chil-
dren where the success of the PCV7 vaccine has been
blunted by a substantial increase in non-PCV7 sero-
type IPD. This suggests that serotype replacement
requires continued surveillance and other epidemio-
logical investigations to monitor the effects of PCV7.
Finally, widespread and rapidly increasing emer-
gence of antimicrobial resistance among pneumococci
has complicated treatment of pneumococcal disease.
Five of the seven serotypes in PCV7 are responsible for
most penicillin-resistant infections. In the United
States, Kyaw et al. [9] demonstrated that rates of resis-
tant disease caused by vaccine serotypes fell by 87%
between 1999 and 2004 (i.e., after the introduction of
universal PCV7 vaccination). The long-term impact
of universal PCV7 vaccination on antimicrobial resis-
tance remains to be established.
Conclusions
The cost-effectiveness evaluation of PCV7 vaccination
in Ireland is sensitive to the indirect protection that a
universal infant vaccination program would confer on
unvaccinated adults, i.e., the herd immunity effect. It is
important to highlight that any economic evaluation is
only as accurate as the data inputs included in the
model. For decision-makers, who accept the herd
Table 3 Variation of parameters in the (a) base-case and (b) herd immunity models in a one-way sensitivity analysis
Model variable Change in parameter
ICER (€/LYG)
Base case
€249,591/LYG
a. Base case
Vaccine cost +50% 370,745
-50% 128,436
Incidence of pneumococcal infection +50% 149,645
-50% 549,429
Case fatality rates +50% 166,394
-50% 499,182
Vaccine efﬁcacy Upper 95% CI 162,639
Lower 95% CI 444,092
Cost of administering vaccine (€15) €20 268,767
€10 230,415
Duration of protection from vaccination (5 years) 10 years 148,243
Onset of protection from vaccination (2–6 months 50%, >months 100%) 2–6 months, 0%; 404,895
>6 months, 100%;
>2 months, 100% 178,524
Serotype coverage for IPD +10% 233,488
-10% 267,924
Vaccine uptake 85% 80% 249,591
90% 249,591
Direct medical costs +50% 226,471
-50% 272,710
Cost of long-term complications from meningitis +50% 247,587
-50% 251,595
Discount rate for costs and beneﬁts 0% 90,857
6% 388,657
Parameter
ICER (€/LYG)
Herd immunity
€5997/LYG
b. Herd immunity
Herd immunity effect restricted to IPD only 51,284
IPD and hospitalized pneumonia 2,583
Herd immunity effect lowered to 5% IPD only 122,358
IPD and hospitalized pneumonia 22,741
Case fatality rates +50% 4,041
-50% 11,621
Direct medical costs +50% 4,992
-50% 7,001
Incidence of pneumococcal infection in adults: +50% 50%
Pneumococcal meningitis 5,975 6,018
Pneumococcal septicemia 5,582 6,484
Hospitalized pneumonia (all-cause) 3,592 11,947
CI, conﬁdence interval; ICER, incremental cost-effectiveness ratio; IPD, invasive pneumococcal disease.
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immunity effect, the results of this analysis indicate
that vaccination is cost-effective in comparison with
several other health-care programs that have been gen-
erally accepted in Ireland (e.g., use of statins [10]).
Source of ﬁnancial support: This study received funding from
the National Immunisation Advisory Committee.
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Outcomes prevented
Direct effect on vaccinated infants
(n = 61,000)
Indirect effect on unvaccinated adults
(n = 2.98 million)
Meningitis 14 2
Bacteremia 22 43
All pneumonia 309 —
Hospitalized pneumonia — 484
All AOM 7358 3343
Deaths (discounted) 1.4 148
Life-years saved (discounted) 41 1269
Direct costs
Cost of vaccination —
Vaccine administration €2.34 million —
Vaccine ingredient cost €9.86 million —
Total €12.2 million
Direct treatment costs avoided
Meningitis €0.26 million €0.02 million
Septicemia €0.14 million €0.30 million
All pneumonia €0.65 million —
Hospitalized pneumonia — €2.24 million
All AOM €1.0 million —
Total €2.05 million €2.56 million
AOM, acute otitis media.
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